Hematologic Oncology

A new drug application has been submitted to Japan's Ministry of Health, Labor and Welfare for quizartinib for the treatment of adult patients with FLT3-ITD–positive acute myeloid leukemia.

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses drug development in acute myeloid leukemia (AML).

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Mary-Beth Percival, MD, discusses the ongoing development of FLT3 inhibitors and other current research in patients with AML.

Jason Valent, MD, oncologist, Cleveland Clinic, discusses the potential application of minimal residual disease (MRD) negativity in patients with multiple myeloma.

Hetty Carraway, MD, oncologist, Cleveland Clinic, discusses predisposition to acute myeloid leukemia (AML).

Aaron Gerds, MD, discusses the activity and drawbacks with current systemic agents in myeloproliferative neoplasms.

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.

Jeffrey A. Zonder, MD, discusses triplet regimens in multiple myeloma and patient eligibility for clinical trials.

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses accelerated phase myelofibrosis.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment considerations for patients with chronic myeloid leukemia.

Lloyd Damon, MD, discusses novel therapies in acute myeloid leukemia, including FLT3 and IDH1/2 inhibitors.

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.

Ehab Atallah, MD, discusses the discontinuation of treatment for patients with chronic myeloid leukemia.

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

Joseph Uberti, MD, PhD, discusses the risk and benefit of a bone marrow transplant for patients with myelodysplastic syndrome.

Jay Yang, MD, explains that drug development is not as simple as identifying a molecular target and matching inhibitor.